A tender decision in Poland just impacted U.S. rebates. Here’s why that’s about to happen constantly.
For the past 25 years, pharmaceutical pricing has operated under a clear geographic hierarchy. The U.S. was expensive, with list prices often three times higher than peer advanced economies. International markets were conservative, constrained by reference price mechanism and budget pressure. The two operated almost independently, governed by separate teams and managed according to separate logic. That era ended in 2024.
Most-Favored Nation (MFN) pricing has fundamentally rewired the relationship between U.S. government programs and international markets. Under the three new frameworks now rolling out (GENEROUS for Medicaid, GLOBE for Medicare Part B, and GUARD for Medicare Part D), a price concession offered anywhere in a reference basket of advanced economies now automatically influences what the U.S. government pays. None of these stays local anymore.
The implications are immediate and material. Confidential rebate data that was never supposed to be benchmarked is now a potential anchor for U.S. rebate calculations, and pricing decisions that once took months to ripple across geographies now do so in weeks.
Why MFN Matters Now
The urgency is not theoretical. As of July 2026, at least 17 major pharmaceutical companies have already signed MFN agreements with the Trump Administration, positioning themselves for participation in the GENEROUS model once final terms are released. GLOBE and GUARD are advancing toward mandatory application for qualifying high-spend products across selected Medicare regions. This is not a future scenario. It is unfolding in real time.
The mechanics differ by program, but the direction is the same: each ties U.S. rebates to international net prices through triggers that are automatic and mandated, not negotiated.
Real-world examples illustrate the scale of exposure. GLP-1 receptor agonists, among the most commercially significant product launches in recent pharma history, have faced demands to compress effective net costs from $1,000–$1,350 per month down to international reference levels around $350. These are not marginal adjustments.
What’s Changing: From Siloed Geography to Integrated Visibility
For decades, the operating model was clear: manage pricing separately by geography, optimize for local market conditions, and accept that the U.S. would be expensive. That decentralized model is no longer tenable.
Under MFN, every pricing decision, including confidential ones, now carries quantifiable cross-border consequences. The old model of siloed systems and manual spreadsheets cannot function in an environment where data flows instantly and triggering mechanisms are automatic. Manufacturers need visibility into their lowest global price points before they make a decision, not after.
Most organizations lack a single source of truth for net pricing, and scenario modeling remains ad hoc and spreadsheet-based, far too slow for an environment where a single decision can trigger multi-million-dollar margin volatility.
Why This Is Different From Past Pricing Pressure
Pharma has faced pricing pressure before. Reference pricing systems have existed in Europe for decades. So what makes MFN fundamentally different?
Three things:
First, automatic triggers. Under MFN, the triggers are statutory and near-automatic, at a speed and scale reference pricing never had.
Second, confidentiality is no protection. Regulators increasingly have access to net price data, and once accessed, it becomes a potential reference point.
Third, it reverses traditional negotiating leverage. A lower price abroad now directly pressures the much larger U.S. business, and some companies are already responding with launch delays and market withdrawals.
What Happens Next
We are already seeing the industry respond. Insmed delayed its Germany launch of Brinsupri, with CEO William Lewis explicitly citing MFN policy uncertainty. Pfizer reached a landmark voluntary agreement with the Trump Administration involving MFN-aligned pricing for new products and substantial U.S. manufacturing commitments. Bristol Myers Squibb has indicated plans to align list prices in certain markets with U.S. levels for new launches. Multiple companies are pausing or reevaluating European launches, according to industry reports and analyst commentary.
These are not isolated incidents. They are the leading edge of a fundamental restructuring of how pharmaceutical companies will make pricing decisions for the next decade.
The question now is not whether MFN will reshape pharma pricing. It will. The question is whether your organization has the operational infrastructure, including governance discipline, data integration, and decision-support capabilities, to navigate it with visibility and control.
Curious where your organization’s exposure is highest? Talk to our team for a clear-eyed read on your risk areas and the capabilities you’ll need to respond with confidence.
